Mono-Linyah

Acne Vulgaris, moderate Vulvovaginal atrophy, Hot flashes + 9 more
Treatment
9 FDA approvals
20 Active Studies for Mono-Linyah

What is Mono-Linyah

NorgestimateThe Generic name of this drug
Treatment SummaryEthinylestradiol is a synthetic form of estrogen that was developed in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was created to be more bioavailable when taken orally, and eventually replaced mestranol in contraceptive pills. The FDA approved ethinylestradiol in 1943.
Ortho Tri Cyclenis the brand name
image of different drug pills on a surface
Mono-Linyah Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ortho Tri Cyclen
Norgestimate
1989
113

Approved as Treatment by the FDA

Norgestimate, commonly known as Ortho Tri Cyclen, is approved by the FDA for 9 uses which include Postmenopausal Osteoporosis and severe menopausal vulvovaginal atrophy .
Postmenopausal Osteoporosis
Used to treat Postmenopausal Osteoporosis in combination with Estradiol
severe menopausal vulvovaginal atrophy
Used to treat severe menopausal vulvovaginal atrophy in combination with Estradiol
Oral Contraceptives
Used to treat Oral Contraceptives in combination with Ethinylestradiol
Acne Vulgaris
Used to treat moderate Acne vulgaris in combination with Ethinylestradiol
Osteoporosis, Postmenopausal
Used to treat Postmenopausal Osteoporosis in combination with Estradiol
moderate Vulvovaginal atrophy
Used to treat moderate Vulvovaginal atrophy in combination with Estradiol
Hot flashes
Used to treat Menopause in combination with Estradiol
moderate Menopausal Vasomotor Symptoms
Used to treat moderate Menopausal Vasomotor Symptoms in combination with Estradiol
Menopause
Used to treat severe Vasomotor Symptoms Associated With Menopause in combination with Estradiol

Effectiveness

How Mono-Linyah Affects PatientsEthinylestradiol is a synthetic form of estrogen that stops the body from releasing hormones that cause ovulation, and reduces the development of blood vessels in the uterus. This drug has a long lasting effect and is generally safe, although it can increase the risk of blood clots. Patients should be informed of this risk before taking the medication.
How Mono-Linyah works in the bodyEthinylestradiol is a synthetic form of the hormone estrogen. It is used in combined oral contraceptives to stop ovulation, thickening cervical mucus to block sperm, and prevent changes in the uterus that could lead to pregnancy. Ethinylestradiol also keeps the uterus from becoming too vascular and increases a protein that binds to hormones in the body.

When to interrupt dosage

The recommended dosage of Mono-Linyah is contingent upon the established condition, including Acne Vulgaris, Hormonal Contraception and Folate supplementation therapy. The measure of dosage diverges, in relation to the mode of delivery as specified in the table below.
Condition
Dosage
Administration
Polycystic Ovarian Syndrome
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
moderate Vulvovaginal atrophy
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
Menopause
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
severe menopausal vulvovaginal atrophy
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
Osteoporosis, Postmenopausal
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
Oral Contraceptives
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
Menorrhagia
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
Hirsutism
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
moderate Menopausal Vasomotor Symptoms
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
Hot flashes
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
Acne Vulgaris
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral
Dysmenorrhea
, 0.25 mg, 0.215 mg, 0.18 mg, 0.09 mg, 0.645 mg
, Kit, Oral, Tablet, Tablet - Oral, Kit - Oral

Warnings

Mono-Linyah has twenty-six contraindications and should not be taken concurrently with any of the circumstances detailed in the table below.Mono-Linyah Contraindications
Condition
Risk Level
Notes
Breast
Do Not Combine
Breast Cancer
Do Not Combine
high risk of arterial thrombotic disease
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Hypersensitivity
Do Not Combine
Venous Thrombosis
Do Not Combine
Pulse Frequency
Do Not Combine
estrogen-sensitive cancer
Do Not Combine
Metrorrhagia
Do Not Combine
Liver Neoplasms
Do Not Combine
There are 20 known major drug interactions with Mono-Linyah.
Common Mono-Linyah Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Norgestimate.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Norgestimate.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Norgestimate.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Norgestimate.
Astemizole
Major
The metabolism of Astemizole can be increased when combined with Norgestimate.
Mono-Linyah Toxicity & Overdose RiskWomen who overdose on birth control may experience irregular bleeding, nausea, vomiting, tenderness in the breasts, abdominal pain, drowsiness, and fatigue. Treatment for overdose should include monitoring of electrolyte levels and signs of metabolic acidosis, as well as providing supportive care.

Mono-Linyah Novel Uses: Which Conditions Have a Clinical Trial Featuring Mono-Linyah?

There are 38 clinical trials in progress to assess the potential of Mono-Linyah to provide Folate supplementation therapy, alleviate Premenstrual Dysphoric Disorder and address the symptoms of Menopause.
Condition
Clinical Trials
Trial Phases
Dysmenorrhea
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
Oral Contraceptives
0 Actively Recruiting
Menopause
0 Actively Recruiting
Polycystic Ovarian Syndrome
8 Actively Recruiting
Not Applicable, Early Phase 1, Phase 4, Phase 1
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
Hirsutism
0 Actively Recruiting
Hot flashes
16 Actively Recruiting
Phase 1, Phase 4, Not Applicable, Early Phase 1, Phase 2
moderate Vulvovaginal atrophy
0 Actively Recruiting
Menorrhagia
0 Actively Recruiting
severe menopausal vulvovaginal atrophy
0 Actively Recruiting

Mono-Linyah Reviews: What are patients saying about Mono-Linyah?

4.7Patient Review
1/13/2020
Mono-Linyah for Acne
I went with Mono-Linyah to treat my acne and it's been great. At the beginning, my hormones were all over the place which led to some anxiety. However, after four months things evened out and now my skin is almost completely clear. I've had no other side effects besides slightly worse cramping during my period and larger breasts.
4.7Patient Review
4/7/2021
Mono-Linyah for Birth Control
I've been pleased with this birth control so far. It caused a bit of nausea at first (but that went away), and my breasts are now sore. Otherwise, I haven't had any real negative reactions like mood swings. I'm also not spotting, which is great since I was on the mini pill before and getting a period every two weeks.
4.7Patient Review
7/11/2018
Mono-Linyah for Birth Control
I haven't had any issues with side effects and my periods have been regular. The packaging could be better, but it's not a big deal. I'm just glad the medication works.
4.3Patient Review
6/11/2018
Mono-Linyah for Acne
This birth control has done wonders for my acne. I haven't had any negative side effects that I can speak of and my skin has never looked better.
4.3Patient Review
5/21/2022
Mono-Linyah for Painful Periods
This birth control has been great in terms of preventing cramps and other period side effects. However, it's worth noting that it's had negative impacts on my mental health. Overall, though, it's manageable.
View All Reviews

Patient Q&A Section about mono-linyah

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of birth control is Mono-Linyah?

"Mono-Linyah is a birth control pill that contains two different hormones: norgestimate (a progestin) and ethinyl estradiol (an estrogen)."

Answered by AI

What is Mono-Linyah generic for?

"Mono-Linyah is a generic birth control pill for women. The hormones in Mono-Linyah, norgestimate and ethinyl estradiol, prevent ovulation and change the cervical and uterine linings to block the movement of sperm and prevent implantation of a fertilized egg."

Answered by AI

What are the side effects of Mono-Linyah birth control?

"The following side effects may occur: nausea, vomiting, headache, bloating, breast tenderness, swelling of the ankles/feet (fluid retention), or weight change. Vaginal bleeding between periods (spotting) or missed/irregular periods may occur, especially during the first few months of use."

Answered by AI

Is Mono-Linyah a good birth control?

"While Mono-Linyah is not 100% effective, it is a safe and effective method of birth control when used properly. If you miss a dose or are late taking your medication, use backup birth control until your next cycle to ensure you are fully protected."

Answered by AI

Clinical Trials for Mono-Linyah

Have you considered Mono-Linyah clinical trials? We made a collection of clinical trials featuring Mono-Linyah, we think they might fit your search criteria.
Have you considered Mono-Linyah clinical trials? We made a collection of clinical trials featuring Mono-Linyah, we think they might fit your search criteria.
Image of University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research Laboratory in Aurora, United States.

MitoQ + Exercise for Menopause-Related Vascular Health

50 - 120
Female
Aurora, CO
This trial tests whether combining moderate aerobic exercise with the antioxidant MitoQ can improve blood vessel function in postmenopausal women who lack estrogen. MitoQ aims to reduce oxidative stress and enhance blood flow by improving mitochondrial function. The study will compare the effects of exercise with MitoQ, exercise alone, and MitoQ alone. MitoQ is a mitochondria-targeted antioxidant that has been studied for its potential to enhance exercise-induced muscle adaptations and improve peak power in untrained middle-aged men.
Phase < 1
Waitlist Available
Paid Trial
University of Colorado Anschutz Medical Center, Clinical Translational Research Center and Exercise Research LaboratoryKerrie L Moreau, PhD
Have you considered Mono-Linyah clinical trials? We made a collection of clinical trials featuring Mono-Linyah, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top